News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Octapharma USA, Inc. Supports Victory for Women Program, Presents Coagulation Research at 65th Annual NHF Meeting
10/1/2013 9:52:30 AM
HOBOKEN, N.J. (October 1, 2013) – Octapharma USA will present seven clinical posters at the National Hemophilia Foundation’s (NHF) 65th Annual Meeting to be held October 3 – 5 in Anaheim, Calif., emphasizing the company’s commitment to support the bleeding disorders community. Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.
As a corporate sponsor, Octapharma USA will also support the Victory for Women (V4W) reception on October 3. V4W is a health initiative to address the critical issues faced by women with bleeding disorders. Program goals are to increase awareness of women’s bleeding disorders so that girls and women receive early, accurate diagnoses, leading to better health outcomes. V4W aims to provide women affected by bleeding disorders with the education, support, skills and resources they need to advocate for their healthcare, financial and social support needs.
The titles of the Octapharma poster presentations are:
- Results of a prospective, non-interventional clinical study in 170 VWD patients with a new generation of VWF/FVIII concentrate in Germany
- Use of double virally inactivated FVII/vWF in 30 children and young people with von Willebrand’s disease – a single centre experience
- Low inhibitor incidence in previously untreated patients with haemophilia A treated with octanate – Update from the PUP-GCP clinical trial
- Clinical Study in Children with Severe Haemophilia A Investigating Efficacy, Immunogenicity, Pharmacokinetics, and Safety of Human-cl rhFVIII
- Clinical Study to Investigate the Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A
- Bleeding frequency and consumption of FVIII concentrate during on-demand and prophylactic treatment with Human-cl rhFVIII in prospective clinical studies in adult patients with severe haemophilia A
- Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate for the Treatment of Congenital Fibrinogen Deficiency
“The impressive array of poster presentations illustrates Octapharma’s strong commitment to advancing coagulation science,” said Octapharma USA President Flemming Nielsen. “Octapharma’s dedication to supporting coagulation research is stronger than ever, paving the way for the medical advances to create life saving therapies for people with bleeding disorders.”
Octapharma USA encourages attendees to visit its conference booth (#12) throughout the three-day event. Product information will be available for wilate® (Von Willebrand Factor/Factor VIII Concentrate, Human), a therapy for treating Von Willebrand Disease (VWD).
Important Risk Information
wilate® is a plasma-derived, stable, highly purified concentrate of freeze-dried human Von Willebrand Factor (VWF) and coagulation factor VIII (FVIII). Two well-established virus inactivation steps are incorporated into the manufacturing process of wilate®, specifically a solvent/detergent (S/D) and terminal dry heat treatment.
wilate® is a Von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe Von Willebrand Disease (VWD), as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.
wilate® is contraindicated for patients who have known anaphylactic or severe systemic reaction to plasma-derived products, any ingredient in the formulation, or components of the container. Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement therapies. FVIII activity should be monitored to avoid sustained excessive FVIII levels. wilate® is made from human plasma. The risk of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jacob disease agent, cannot be completely eliminated. The most common adverse reactions to treatment with wilate® in patients with VWD have been uticaria and dizziness. The most serious adverse reactions to treatment with wilate® have been hypersensitivity reactions.
For more information and full prescribing on wilate®, please visit www.wilateusa.com.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG is the world’s largest independent human protein products manufacturer and has been committed to patient care and medical innovation for 30 years. With a broad and expanding pipeline, Octapharma’s core business is the development, production, and sale of high quality human protein therapies from both human plasma and human cell-lines, including intravenous immunoglobulin and von Willebrand Factor/Coagulation Factor VIII Complex. Octapharma employs 5,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, New Jersey. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharma.com,
www.wilateusa.com or www.octaplasus.com.
Yankee Public Relations
Help employers find you! Check out all the jobs and post your resume.